Last mentioned: Feb 26, 2026
Agilent reported a 4.4% core revenue growth in Q1 2026, driven by a strong 7% uptick in the pharmaceutical sector despite an 8% decline in academic and government markets. The company is navigating margin pressures from new tariffs while leaning into high-growth areas like GLP-1 manufacturing and CDMO services.
This page surfaces every story mentioning Padraig McDonnell across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Padraig McDonnell was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |